Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus

American Journal of Cardiology

Volumn 118, Issue 11, 2016, Pages 1774-1780

  Tang, Huilin ^a,b   Fang, Zhenwei ^c   Wang, Tiansheng ^d   Cui, Wei ^e   Zhai, Suodi ^a   Song, Yiqing ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b INDIANA UNIVERSITY   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^e THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SLC5A2 PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL ASSESSMENT; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; EMBASE; EVIDENCE BASED PRACTICE; HEART FAILURE; HUMAN; MEDLINE; META ANALYSIS; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; ANTAGONISTS AND INHIBITORS; BLOOD; CAUSE OF DEATH; COMPLICATION; DIABETES MELLITUS, TYPE 2; HEALTH; METABOLISM; MORTALITY; RISK FACTOR; SURVIVAL RATE; TRENDS;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; SURVIVAL RATE;

EID: 84995545603     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.08.061     Document Type: Review

References (30)

1. 1 Marsenic, O., Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 53 (2009), 875–883.
2. 2 Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D.R., Tsapas, A., Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 262–274.
3. 3 Hirshberg, B., Raz, I., Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care 34:Suppl 2 (2011), S101–S106.
4. 4 Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., Broedl, U.C., Inzucchi, S.E., Investigators E-RO. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
5. 5 DeFronzo, R.A., The EMPA-REG study: what has it told us? A diabetologist's perspective. J Diabetes Complications 30 (2016), 1–2.
6. 6 Mills, E.J., Ioannidis, J.P.A., Thorlund, K., Schunemann, H.J., Puhan, M.A., Guyatt, G.H., How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 308 (2012), 1246–1253.
7. 7 Hutton, B., Salanti, G., Caldwell, D.M., Chaimani, A., Schmid, C.H., Cameron, C., Ioannidis, J.P., Straus, S., Thorlund, K., Jansen, J.P., Mulrow, C., Catala-Lopez, F., Gotzsche, P.C., Dickersin, K., Boutron, I., Altman, D.G., Moher, D., The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162 (2015), 777–784.
8. 8 Higgins, J.P.T., Altman, D.G., Sterne, A.C., Chapter 8: assessing risk of bias in included studies. Higgins, J., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 510 (Updated March 2011), 2011, The Cochrane Collaboration Available at: http://handbook.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm. Accessed on February 9, 2016.
9. 9 Bradburn, M.J., Deeks, J.J., Berlin, J.A., Russell Localio, A., Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26 (2007), 53–77.
10. 10 Keus, F., Wetterslev, J., Gluud, C., Gooszen, H.G., van Laarhoven, C.J., Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. Am J Gastroenterol 104 (2009), 546–551.
11. 11 White, I.R., Barrett, J.K., Jackson, D., Higgins, J.P., Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 3 (2012), 111–125.
12. 12 Chaimani, A., Higgins, J.P., Mavridis, D., Spyridonos, P., Salanti, G., Graphical tools for network meta-analysis in STATA. PLoS One, 8, 2013, e76654.
13. 13 Salanti, G., Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 3 (2012), 80–97.
14. 14 Turner, R.M., Davey, J., Clarke, M.J., Thompson, S.G., Higgins, J.P., Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 41 (2012), 818–827.
15. 15 Veroniki, A.A., Vasiliadis, H.S., Higgins, J.P., Salanti, G., Evaluation of inconsistency in networks of interventions. Int J Epidemiol 42 (2013), 332–345.
16. 16 Higgins, J.P., Jackson, D., Barrett, J.K., Lu, G., Ades, A.E., White, I.R., Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3 (2012), 98–110.
17. 17 Lau, J., Schmid, C.H., Chalmers, T.C., Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 48 (1995), 45–57 discussion 59–60.
18. 18 Chaimani, A., Salanti, G., Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods 3 (2012), 161–176.
19. 19 Cefalu, W.T., Leiter, L.A., de Bruin, T.W., Gause-Nilsson, I., Sugg, J., Parikh, S.J., Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 38 (2015), 1218–1227.
20. 20 Leiter, L.A., Cefalu, W.T., de Bruin, T.W., Gause-Nilsson, I., Sugg, J., Parikh, S.J., Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 62 (2014), 1252–1262.
21. 21 Ferrannini, E., Berk, A., Hantel, S., Pinnetti, S., Hach, T., Woerle, H.J., Broedl, U.C., Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 36 (2013), 4015–4021.
22. 22 Lewin, A., DeFronzo, R.A., Patel, S., Liu, D., Kaste, R., Woerle, H.J., Broedl, U.C., Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 38 (2015), 394–402.
23. 23 DeFronzo, R.A., Lewin, A., Patel, S., Liu, D., Kaste, R., Woerle, H.J., Broedl, U.C., Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38 (2015), 384–393.
24. 24 Savarese, G., D'Amore, C., Federici, M., De Martino, F., Dellegrottaglie, S., Marciano, C., Ferrazzano, F., Losco, T., Lund, L.H., Trimarco, B., Rosano, G.M., Perrone-Filardi, P., Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis. Int J Cardiol 220 (2016), 595–601.
25. 25 Wu, J.H., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundstrom, J., Neal, B., Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The Lancet Diabetes Endocrinol 4 (2016), 411–419.
26. 26 Inzucchi, S.E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.M., Woerle, H.J., Broedl, U.C., Johansen, O.E., SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12 (2015), 90–100.
27. 27 Monami, M., Nardini, C., Mannucci, E., Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16 (2014), 457–466.
28. 28 Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S., Woerle, H.J., Broedl, U.C., Johansen, O.E., Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.
29. 29 Palombo, C., Kozakova, M., Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications. Vascul Pharmacol 77 (2016), 1–7.
30. 30 Bolinder, J., Ljunggren, O., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A.M., Sugg, J., Parikh, S., Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocr Metab 97 (2012), 1020–1031.